Can-Fite BioPharma Files Prospectus For Offering ~6.599M Ordinary Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1536196/000121390026103584/ea0306467-f3_canfite.htm
Stocks · News reference
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of $(4.29) per share from
Can-Fite BioPharma Says Blinded Overall Survival In Pivotal Phase 3 Namodenoson Liver Cancer Study Appears Longer Than Originally Anticipated; Evaluating Earlier Timing For Planned Interim Analysis